Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus DHAP salvage therapy before autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma
NL-OMON47390Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin, cisplatin, cytarabine and dexamethasone in classical Hodgkin lymphoma (cHL), sponsored by Amsterdam University Medical Center. Primary endpoints: Phase I recommended dose level and PET-negative metabolic complete remission after 3 courses. Started Apr 2014; status: active, not recruiting.
02
Drugs
brentuximab vedotincisplatincytarabinedexamethasone
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON47390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47390.